- Home
- ELTX vs STRW Comparison
ELTX vs STRW Comparison
Compare ELTX & STRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELTX | STRW |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.4M | 171.8M |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ELTX | STRW |
|---|---|---|
| Price | $11.34 | $13.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $18.00 | $13.88 |
| AVG Volume (30 Days) | ★ 123.3K | 17.2K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 5.17% |
| EPS Growth | ★ 39.29 | 5.26 |
| EPS | N/A | ★ 0.17 |
| Revenue | $2,301,000.00 | ★ $154,999,000.00 |
| Revenue This Year | N/A | $8.52 |
| Revenue Next Year | N/A | $3.95 |
| P/E Ratio | ★ N/A | $77.79 |
| Revenue Growth | N/A | ★ 32.41 |
| 52 Week Low | $6.92 | $9.99 |
| 52 Week High | $14.93 | $14.00 |
Technical Indicators
Market Signals| Indicator | ELTX | STRW |
|---|---|---|
| Relative Strength Index (RSI) | 55.50 | 57.62 |
| Support Level | $9.63 | $12.59 |
| Resistance Level | $11.47 | $13.36 |
| Average True Range (ATR) | 0.98 | 0.28 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 59.84 | 91.27 |
Price Performance
Historical ComparisonAbout ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
About STRW Strawberry Fields REIT Inc.
Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.